This content is for informational and research purposes only. Not medical advice. Consult a licensed physician before starting any hormone or peptide therapy.

BPC-157 — formally, Body Protection Compound, which is either the most ambitious or most honest name in peptide research, depending on how you look at it — has the kind of fanbase usually reserved for classic cars and sourdough starters. People who have run it are evangelical about it. People who haven't are skeptical of people who have. And somewhere in the middle, there is a genuinely interesting body of research on a 15-amino-acid peptide that has been studied for its effects on tissue repair, gut health, tendon healing, and inflammatory modulation.

This guide is for people who want to understand the science, not just the mythology. What does BPC-157 actually do, what does the research show about BPC-157 dosing, how do you run the BPC-157 protocol properly, and what do you actually need to track?

What Is BPC-157? (Body Protection Compound Explained)

BPC-157 is a synthetic pentadecapeptide — a chain of 15 amino acids — derived from a protein found in human gastric juice. That last part surprises people. This is not some exotic compound synthesized entirely in a lab from imagination; the parent protein it's derived from, BPC (Body Protection Compound), occurs naturally in the gastric system, where it plays a cytoprotective role. BPC-157 is a partial sequence of that protein, selected and synthesized because it appears to retain — and in some contexts, amplify — the cytoprotective properties of the full compound.

The "protection" in the name is not marketing. Research on BPC-157 in animal models shows effects on:

The caveat that needs to be stated clearly and then set aside so we can continue: essentially all BPC-157 research is in animal models, predominantly rodents. There is limited human clinical trial data. This is a meaningful limitation. It's also why the compound is categorized as a research peptide rather than an approved drug. The mechanism makes biological sense; the human data to confirm dose-response and efficacy is still limited. That's the honest picture.

BPC-157 Dosing: What the Research Actually Says

The research literature on BPC-157 dosing in animal models uses a range of doses, but when extrapolated to human body weight equivalents, most practitioner protocols land in the range of 200–500 mcg per day, typically split into one or two injections.

Frequency: once or twice daily. The BPC-157 half-life is relatively short — estimated at around 4 hours in plasma — which is why twice-daily dosing is commonly used in protocols targeting active injury repair. For systemic or maintenance use, once-daily dosing is more common and more practical.

The short half-life is one reason precise logging matters here. Twice daily at 250 mcg is a different protocol than once daily at 500 mcg, even though the daily total is identical. Your injection schedule should reflect your intention.

Systemic vs Local BPC-157 Injection

One of the more interesting features of BPC-157 in the research literature is that it appears to work both locally (injected at or near the injury site) and systemically (injected subcutaneously anywhere, typically the abdomen). This gives it flexibility that most peptides don't have.

Systemic injection (subcutaneous, abdomen)

Subcutaneous injection near the abdomen is the most common approach for systemic BPC-157 use. This is the standard BPC-157 injection site approach for gut health applications, general cytoprotective effects, and when targeting injuries where direct injection isn't practical. The abdomen offers consistent subcutaneous tissue depth and easy site rotation.

Local injection (directly at injury site)

For tendon, ligament, or muscle injuries, some protocols use intramuscular or subcutaneous injection directly at or proximate to the injury site. The hypothesis is that local delivery concentrates the compound at the target tissue. Animal model data supports this approach for acute tendon injuries specifically. It's worth noting that injecting near an inflamed or injured area requires care — intramuscular injection around a genuine injury carries risks that subcutaneous injection does not, and this is one area where physician oversight is genuinely useful rather than just a legal disclaimer.

The practical answer: local injection sounds more dramatic and produces slightly better cocktail party anecdotes, but both approaches appear to work. Pick what aligns with your intended use. If you're running BPC-157 for gut health, abdomen subQ is the obvious choice. If you're targeting a specific injury, local injection is worth considering — with appropriate caution about technique.

Reconstituting BPC-157: The Practical Guide

BPC-157 comes as a lyophilized (freeze-dried) powder, typically in vials of 5mg. You'll need to reconstitute it yourself, which is where a lot of people make preventable mistakes. The BPC-157 reconstitution guide is essentially: use bacteriostatic water, do the math correctly, and don't shake the vial.

What you need

The reconstitution math

This is the calculation that trips people up, but it's straightforward once you see it clearly. The goal is to arrive at a concentration that makes your dose easy to measure with an insulin syringe.

A common approach for a 5mg vial:

Adjust the bacteriostatic water volume to create a concentration that gives you clean, readable measurements for your dose. Some people prefer 5mL of water (1,000 mcg/mL, 10 mcg per unit) for finer measurement precision. Either works; what matters is doing the math once, writing it down, and not redoing it from memory at injection time.

Storage

Lyophilized (pre-reconstitution): refrigerate, use within 18–24 months of purchase if stored properly. Some sources suggest room temperature is acceptable for short periods, but refrigeration is safer.

Reconstituted: refrigerate always. Bacteriostatic water extends stability to approximately 28–30 days. After that, discard. Do not freeze reconstituted BPC-157. Log the reconstitution date on your vial so you know when 30 days are up — not because you'll remember, but because you won't.

BPC-157 Injection Schedule and Logging Your Protocol

Research protocols typically use BPC-157 in 4–8 week cycles, followed by a break. There isn't strong evidence for or against continuous long-term use, and the cycling approach is largely precautionary given the limited long-term human data.

A standard research cycle might look like:

Why logging your BPC-157 injection schedule matters:

Site rotation

Twice-daily subcutaneous injections in the same location will cause subcutaneous tissue irritation and nodule formation over time. Rotating sites — left abdomen, right abdomen, outer thigh — distributes this and prevents cumulative tissue irritation. You cannot effectively rotate sites if you're not tracking where you last injected. This is more relevant for BPC-157 than for once-weekly peptides because the injection frequency is higher.

Correlating with recovery

If you're running BPC-157 for injury recovery, the most valuable thing you can do is log your subjective pain or function markers — range of motion, pain score, functional capacity — alongside your injection log. This lets you see whether recovery correlates with the protocol, whether it plateaued, and whether a second cycle produced the same response. Without this data, you're just healing over time and attributing it to the peptide because that's what feels right. Maybe it is the peptide. Log it and find out.

ZAP tracks peptide injection schedules, site rotation, and allows you to log subjective markers daily alongside your dose history. If you're running BPC-157 alongside a TRT protocol, both compound logs live in the same place, with serum modeling for your testosterone running in parallel.